Eligible participants had a BMI of >= 24 kg/m^2 and dyslipidemia (TG >= 1.7 mmol·L^(-1) or TC >= 5.2 mmol·L^(-1)), and were free from major chronic conditions.
Conditions
Interventions
Trial group (spermidine):Spermidine capsules 10 mg/day
Control group (placebo):Placebo 10 mg/day
Sponsors
Shanghai Tenth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Age between 18 and 60 years; 2. No restrictions on gender; 3. Body Mass Index (BMI) >= 24 kg/m^2; 4. Documented dyslipidemia (Triglycerides >= 1.7 mmol·L^(-1) or Total Cholesterol >= 5.2 mmol·L^(-1)); 5. Provides signed and dated informed consent;
Exclusion criteria
Exclusion criteria: 1.Diagnosis of acute or severe gastrointestinal disease; 2.Concurrent participation in any other weight-loss therapy; 3.Current use of hypoglycemic or lipid-lowering medications; 4.Participation in any other clinical trial within one month prior to signing the informed consent form; 5.Pregnancy, lactation, or planning a pregnancy during the trial period; 6.Known allergy to cellulose or wheat; 7.History of cancer; 8.Renal insufficiency, indicated by abnormal serum creatinine levels; 9.Hepatic impairment, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 × upper limit of normal (ULN), or total bilirubin (TBIL) >3 × ULN; 10.Any other condition deemed by the investigator as inappropriate for trial participation;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Triglycerides (TG); | — |
Secondary
| Measure | Time frame |
|---|---|
| Appetite Score;Quality of Life;Alanine Aminotransferase;Fasting Blood Glucose;Physical Activity Intensity;Low-Density Lipoprotein Cholesterol;Total Cholesterol (TC);Creatinine;Anthropometric Measurements; | — |
Countries
China
Contacts
Public ContactBu Le
Shanghai Tenth People's Hospital
Outcome results
None listed